Intra-Cellular Therapies, Inc. financial data

Symbol
ITCI on Nasdaq
Industry
Pharmaceutical Preparations
Location
135 Route 202/206, Suite 6, Bedminster, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
Oneida Resources Corp. (to 8/29/2013)
Latest financial report
10-K - Q4 2024 - Feb 21, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 678 % -2.62%
Quick Ratio 12.8 % -59%
Debt-to-equity 17.9 % -4.64%
Return On Equity -7.4 % +67.8%
Return On Assets -6.28 % +67.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 107M shares +0.9%
Common Stock, Shares, Outstanding 106M shares +10.2%
Entity Public Float 7.1B USD +18.3%
Common Stock, Value, Issued 11K USD +10%
Weighted Average Number of Shares Outstanding, Basic 103M shares +7.56%
Weighted Average Number of Shares Outstanding, Diluted 103M shares +7.56%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 681M USD +46.6%
Research and Development Expense 236M USD +31.1%
General and Administrative Expense 471M USD +17.9%
Operating Income (Loss) -117M USD +26.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -74.2M USD +46.6%
Income Tax Expense (Benefit) 473K USD -25.6%
Net Income (Loss) Attributable to Parent -74.7M USD +46.5%
Earnings Per Share, Basic -0.73 USD/shares +50%
Earnings Per Share, Diluted -0.73 USD/shares +50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 307M USD +108%
Accounts Receivable, after Allowance for Credit Loss, Current 167M USD +46%
Inventory, Net 26.3M USD +126%
Assets, Current 1.31B USD +95.8%
Property, Plant and Equipment, Net 1.47M USD -11.2%
Operating Lease, Right-of-Use Asset 13.4M USD +3.87%
Other Assets, Noncurrent 5.76M USD -21%
Assets 1.37B USD +87.7%
Accounts Payable, Current 26.1M USD +128%
Liabilities, Current 206M USD +66.5%
Operating Lease, Liability, Noncurrent 12.7M USD -4.34%
Liabilities 218M USD +59.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 191K USD +83.7%
Retained Earnings (Accumulated Deficit) -1.69B USD -4.62%
Stockholders' Equity Attributable to Parent 1.15B USD +94.2%
Liabilities and Equity 1.37B USD +87.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34.1M USD +43.2%
Net Cash Provided by (Used in) Financing Activities 9.99M USD +174%
Net Cash Provided by (Used in) Investing Activities 16.2M USD
Common Stock, Shares Authorized 175M shares 0%
Common Stock, Shares, Issued 106M shares +10.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -7.95M USD +89.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 309M USD +106%
Deferred Tax Assets, Valuation Allowance 297M USD +9.93%
Operating Lease, Liability 17M USD +0.25%
Depreciation 132K USD -1.49%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -74.6M USD +44.9%
Lessee, Operating Lease, Liability, to be Paid 20.7M USD -4.28%
Operating Lease, Liability, Current 4.23M USD +17.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.51M USD +15.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.44M USD +17%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.7M USD -20.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.57M USD +15.1%
Deferred Tax Assets, Operating Loss Carryforwards 130M USD -6.22%
Unrecognized Tax Benefits 2.4M USD -4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.71M USD +17%